216 related articles for article (PubMed ID: 22724467)
21. An update on heparins at the beginning of the new millennium.
Fareed J; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
[TBL] [Abstract][Full Text] [Related]
22. Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
Florian-Kujawski M; Hoppensteadt D; Maddineni J; Ziegler H; Fareed J
Int Angiol; 2004 Dec; 23(4):346-54. PubMed ID: 15767980
[TBL] [Abstract][Full Text] [Related]
23. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
[TBL] [Abstract][Full Text] [Related]
24. Comparative pharmacokinetics of LMWHs.
Samama MM; Gerotziafas GT
Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
[TBL] [Abstract][Full Text] [Related]
25. The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
Mousa SA
Cardiovasc Drug Rev; 2002; 20(3):199-216. PubMed ID: 12397367
[TBL] [Abstract][Full Text] [Related]
26. The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement.
Gionis MN; Ioannou CV; Katsamouris AN; Katonis P; Balalis K; Sfyridaki K; Elalamy I; Gerotziafas GT
Thromb Res; 2013; 132(6):685-91. PubMed ID: 24182549
[TBL] [Abstract][Full Text] [Related]
27. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
Walenga JM; Jeske WP; Samama MM; Frapaise FX; Bick RL; Fareed J
Expert Opin Investig Drugs; 2002 Mar; 11(3):397-407. PubMed ID: 11866668
[TBL] [Abstract][Full Text] [Related]
28. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
29. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
Hoppensteadt D; Walenga JM; Fareed J; Bick RL
Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
[TBL] [Abstract][Full Text] [Related]
30. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
[TBL] [Abstract][Full Text] [Related]
31. Influence of different anticoagulant agents on fibrinopeptide a generation.
Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437
[TBL] [Abstract][Full Text] [Related]
32. Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay.
Bourti Y; Fazavana J; Armand M; Saller F; Lasne D; Borgel D; Bianchini EP
Thromb Haemost; 2016 Aug; 116(3):452-60. PubMed ID: 27412396
[TBL] [Abstract][Full Text] [Related]
33. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
Bauer KA
Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
Padilla A; Gray E; Pepper DS; Barrowcliffe TW
Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
Samama MM; Gerotziafas GT
Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
[TBL] [Abstract][Full Text] [Related]
36. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
[TBL] [Abstract][Full Text] [Related]
37. Biochemistry and clinical pharmacology of new anticoagulant agents.
Samama MM; Gerotziafas GT; Elalamy I; Horellou MH; Conard J
Pathophysiol Haemost Thromb; 2002; 32(5-6):218-24. PubMed ID: 13679646
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
Mousa SA
Semin Thromb Hemost; 2000; 26 Suppl 1():39-46. PubMed ID: 11011805
[TBL] [Abstract][Full Text] [Related]
39. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation.
Ben-Hadj-Khalifa S; Hézard N; Almawi WY; Remy MG; Florent B; Mahjoub T; Nguyen P
Blood Coagul Fibrinolysis; 2011 Jul; 22(5):369-73. PubMed ID: 21577096
[TBL] [Abstract][Full Text] [Related]
40. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography.
Hacquard M; Perrin J; Lelievre N; Vigneron C; Lecompte T
Thromb Res; 2011 Jan; 127(1):29-34. PubMed ID: 20850172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]